Literature DB >> 11122237

Production of transforming growth factor-beta 1 (TGF-beta1) by blood monocytes from patients with different clinical forms of leprosy.

I M Goulart1, J R Mineo, N T Foss.   

Abstract

In the present study, the concentration of TGF-beta1 secreted by adherent cells isolated from human peripheral blood mononuclear cells (PBMC) and either stimulated with PGL-1 or lipopolysaccharide (LPS) or left unstimulated was determined by ELISA. The cells were isolated from untreated patients with different clinical forms of leprosy and healthy individuals. The adherent cells exhibited spontaneous release of TGF-beta1 in all clinical forms of leprosy and in healthy individuals; however, lepromatous leprosy/borderline leprosy (LL/BL) patients presenting erythema nodosum leprosum (ENL) displayed significantly higher concentrations of TGF-beta1 than either the other patients studied or the controls. These high TGF-beta1 levels were consistently observed when LL/BL ENL cells were stimulated with phenolic glycolipid (PGL-1) or LPS, and even in the absence of a stimulus (P < 0.01). The most significant differences in TGF-beta1 levels were observed when comparing the results in the presence of PGL-1 from ENL with, in order of significance: tuberculoid leprosy (TT) patients (P < 0.001), LL/BL patients without ENL (P < 0.01), healthy individuals (P < 0.01) and borderline-borderline/borderline-tuberculoid (BB/BT) patients with reversal reaction (RR) (P < 0.01). The BB/BT patients produced equivalent levels of TGF-beta1 compared with LL/BL patients without ENL, for all types of stimuli (P > 0.05). In contrast, TT patients produced the lowest levels of TGF-beta1 among all the subjects studied (both patients and healthy controls), especially following PGL-1 stimulation (P < 0.001, and P < 0.05, respectively). In conjunction with our previous data regarding TGF-beta1 expression in dermal lesions, it appears that TGF-beta1 probably plays different roles in leprosy: (i) to mediate a suppressive action locally, associated with the presence of PGL-1, and (ii) to induce proinflammatory effects when secreted systemically by monocytes, thereby acting as a modulatory cytokine in the acute inflammatory reactions of ENL and associated with the Th2 immune response in multibacillary forms of leprosy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122237      PMCID: PMC1905808          DOI: 10.1046/j.1365-2249.2000.01376.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Cytokine patterns of immunologically mediated tissue damage.

Authors:  M Yamamura; X H Wang; J D Ohmen; K Uyemura; T H Rea; B R Bloom; R L Modlin
Journal:  J Immunol       Date:  1992-08-15       Impact factor: 5.422

2.  Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactions.

Authors:  S K Parida; G E Grau; S A Zaheer; R Mukherjee
Journal:  Clin Immunol Immunopathol       Date:  1992-04

Review 3.  The Th1/Th2 paradigm.

Authors:  S Romagnani
Journal:  Immunol Today       Date:  1997-06

4.  Transforming growth factor beta induces the production of interleukin 6 by human peripheral blood mononuclear cells.

Authors:  M Turner; D Chantry; M Feldmann
Journal:  Cytokine       Date:  1990-05       Impact factor: 3.861

5.  Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism.

Authors:  M Barral-Netto; A Barral; C E Brownell; Y A Skeiky; L R Ellingsworth; D R Twardzik; S G Reed
Journal:  Science       Date:  1992-07-24       Impact factor: 47.728

Review 6.  TGF beta and HIV infection.

Authors:  M Lotz; P Seth
Journal:  Ann N Y Acad Sci       Date:  1993-06-23       Impact factor: 5.691

7.  Transforming growth factor-beta primes macrophages to express inflammatory gene products in response to particulate stimuli by an autocrine/paracrine mechanism.

Authors:  P W Noble; P M Henson; C Lucas; M Mora-Worms; P C Carré; D W Riches
Journal:  J Immunol       Date:  1993-07-15       Impact factor: 5.422

8.  Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease.

Authors:  M M Shull; I Ormsby; A B Kier; S Pawlowski; R J Diebold; M Yin; R Allen; C Sidman; G Proetzel; D Calvin
Journal:  Nature       Date:  1992-10-22       Impact factor: 49.962

9.  Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death.

Authors:  A B Kulkarni; C G Huh; D Becker; A Geiser; M Lyght; K C Flanders; A B Roberts; M B Sporn; J M Ward; S Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

10.  Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.

Authors:  A L Moreira; E P Sampaio; A Zmuidzinas; P Frindt; K A Smith; G Kaplan
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

View more
  8 in total

Review 1.  Manipulation of the mononuclear phagocyte system by Mycobacterium tuberculosis.

Authors:  Geanncarlo Lugo-Villarino; Olivier Neyrolles
Journal:  Cold Spring Harb Perspect Med       Date:  2014-08-21       Impact factor: 6.915

2.  Mycobacterium leprae actively modulates the cytokine response in naive human monocytes.

Authors:  Daniel Sinsimer; Dorothy Fallows; Blas Peixoto; James Krahenbuhl; Gilla Kaplan; Claudia Manca
Journal:  Infect Immun       Date:  2009-10-19       Impact factor: 3.441

3.  Mycobacterium leprae infection in monocyte-derived dendritic cells and its influence on antigen-presenting function.

Authors:  Ken Hashimoto; Yumi Maeda; Hiroaki Kimura; Koichi Suzuki; Akihiro Masuda; Masanori Matsuoka; Masahiko Makino
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

Review 4.  A Systematic Review of Immunological Studies of Erythema Nodosum Leprosum.

Authors:  Anastasia Polycarpou; Stephen L Walker; Diana N J Lockwood
Journal:  Front Immunol       Date:  2017-03-13       Impact factor: 7.561

5.  miRNome Expression Analysis Reveals New Players on Leprosy Immune Physiopathology.

Authors:  Claudio Guedes Salgado; Pablo Pinto; Raquel Carvalho Bouth; Angélica Rita Gobbo; Ana Caroline Cunha Messias; Tatiana Vinasco Sandoval; André Mauricio Ribeiro Dos Santos; Fabiano Cordeiro Moreira; Amanda Ferreira Vidal; Luiz Ricardo Goulart; Josafá Gonçalves Barreto; Moisés Batista da Silva; Marco Andrey Cipriani Frade; John Stewart Spencer; Sidney Santos; Ândrea Ribeiro-Dos-Santos
Journal:  Front Immunol       Date:  2018-03-09       Impact factor: 7.561

6.  Type 2 leprosy reaction presenting as a monoarthritis post multidrug therapy.

Authors:  Isabela Maria Bernardes Goulart; Marcela Araujo de Oliveira Santana; Willian Vargas Tenório da Costa; Matthew Martin Pavelka; Bruno de Carvalho Dornelas
Journal:  IDCases       Date:  2022-01-06

7.  CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes.

Authors:  Jong R Kim; Nathan C Horton; Stephen O Mathew; Porunelloor A Mathew
Journal:  Inflamm Res       Date:  2013-05-22       Impact factor: 4.575

8.  The Effects of Prednisolone Treatment on Cytokine Expression in Patients with Erythema Nodosum Leprosum Reactions.

Authors:  Edessa Negera; Stephen L Walker; Kidist Bobosha; Yonas Bekele; Birtukan Endale; Azeb Tarekegn; Markos Abebe; Abraham Aseffa; Hazel M Dockrell; Diana N Lockwood
Journal:  Front Immunol       Date:  2018-02-09       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.